Phase IIb/III trial to evaluate thymosin beta 4 (RGN 259) in patients with moderate to severe dry-eye syndrome
Status: Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 06 Aug 2015
Price : $35 *
At a glance
- Drugs Timbetasin (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors G-treeBNT
- 06 Aug 2015 Status changed from planning to not yet recruiting according to RegeneRx media release.
- 17 Jul 2015 According to RegeneRx media release, company has recently received an IND for this trial.
- 17 Feb 2015 According to a RegenRx media release, G-treeBNT filed an IND for this phase IIb/III trial in South Korea in Dec 2014, it is expected to be initiated in 2015, with results in 2016.